Your browser is no longer supported. Please, upgrade your browser.
Lexicon Pharmaceuticals, Inc.
Index- P/E13.49 EPS (ttm)0.39 Insider Own0.50% Shs Outstand144.45M Perf Week3.78%
Market Cap763.06M Forward P/E- EPS next Y-0.26 Insider Trans0.00% Shs Float138.37M Perf Month-2.43%
Income38.10M PEG- EPS next Q-0.18 Inst Own84.00% Short Float2.53% Perf Quarter47.04%
Sales7.10M P/S107.47 EPS this Y-147.40% Inst Trans-0.44% Short Ratio3.66 Perf Half Y2.76%
Book/sh0.95 P/B5.49 EPS next Y49.20% ROA20.40% Target Price13.00 Perf Year289.55%
Cash/sh0.81 P/C6.44 EPS next 5Y- ROE28.50% 52W Range1.03 - 9.65 Perf YTD52.63%
Dividend- P/FCF- EPS past 5Y-63.50% ROI-27.90% 52W High-45.91% Beta1.40
Dividend %- Quick Ratio- Sales past 5Y-28.70% Gross Margin91.10% 52W Low406.80% ATR0.31
Employees78 Current Ratio3.80 Sales Q/Q-97.80% Oper. Margin- RSI (14)50.40 Volatility4.22% 5.98%
OptionableYes Debt/Eq0.09 EPS Q/Q80.60% Profit Margin- Rel Volume0.37 Prev Close5.21
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume957.05K Price5.22
Recom2.50 SMA20-2.48% SMA508.76% SMA200-1.76% Volume354,519 Change0.19%
Jan-29-21Upgrade JP Morgan Underweight → Neutral $7
Jan-29-21Downgrade Wedbush Outperform → Neutral $2 → $8
Dec-08-20Upgrade Citigroup Neutral → Buy
Nov-18-20Upgrade Gabelli & Co Hold → Buy
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19Upgrade Gabelli & Co Sell → Hold
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Oct-06-21 04:28AM  
Sep-15-21 08:00AM  
Aug-30-21 07:00AM  
Aug-23-21 09:45AM  
Jul-30-21 08:35AM  
Jul-28-21 05:40PM  
Jul-22-21 03:03PM  
Jun-25-21 08:00AM  
May-26-21 04:15PM  
May-13-21 04:15PM  
May-06-21 08:35PM  
May-03-21 06:02AM  
Apr-29-21 04:14PM  
Apr-19-21 12:30PM  
Apr-08-21 04:35PM  
Mar-15-21 08:36AM  
Mar-10-21 05:55PM  
Mar-04-21 04:05PM  
Mar-03-21 12:40PM  
Mar-02-21 10:02AM  
Mar-01-21 10:33AM  
Feb-26-21 10:13AM  
Feb-11-21 11:05AM  
Feb-06-21 06:55AM  
Jan-31-21 02:55AM  
Jan-29-21 06:56AM  
Jan-22-21 10:18AM  
Jan-20-21 12:13PM  
Jan-15-21 08:31AM  
Jan-14-21 08:00AM  
Jan-06-21 08:00AM  
Jan-04-21 09:40AM  
Dec-31-20 08:00AM  
Dec-16-20 04:05PM  
Dec-12-20 04:03PM  
Dec-11-20 06:04PM  
Dec-09-20 09:22AM  
Nov-16-20 10:02PM  
Nov-06-20 07:48AM  
Oct-29-20 10:05AM  
Oct-27-20 08:00AM  
Sep-23-20 06:43PM  
Sep-14-20 09:46AM  
Sep-08-20 04:05PM  
Sep-04-20 08:00AM  
Sep-03-20 06:00PM  
Aug-24-20 11:35AM  
Aug-10-20 11:52AM  
Aug-03-20 07:25AM  
Aug-02-20 09:54AM  
Jul-30-20 06:00PM  
Jul-23-20 07:00AM  
Jul-22-20 12:32PM  
Jul-21-20 07:00AM  
Jul-20-20 07:00AM  
Jul-14-20 01:19PM  
Jul-04-20 02:02PM  
Jun-13-20 11:01AM  
Jun-11-20 05:22PM  
May-27-20 07:00AM  
May-13-20 05:30PM  
Apr-27-20 06:33PM  
Apr-22-20 05:41PM  
Apr-20-20 10:04AM  
Apr-07-20 07:00AM  
Mar-30-20 11:11AM  
Mar-20-20 07:44AM  
Mar-19-20 04:01PM  
Mar-13-20 08:05AM  
Mar-12-20 01:40PM  
Mar-05-20 07:00AM  
Mar-04-20 12:30PM  
Jan-24-20 03:00PM  
Jan-20-20 04:01PM  
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Swain Judith LDirectorApr 24Option Exercise0.0010,638027,006Apr 27 04:51 PM
SOBECKI CHRISTOPHER JDirectorApr 24Option Exercise0.0010,6380151,397Apr 27 04:50 PM
Palantoni FrankDirectorApr 24Option Exercise0.0010,638027,006Apr 27 04:49 PM
LEFKOWITZ ROBERT J MDDirectorApr 24Option Exercise0.0010,638027,006Apr 27 04:48 PM
NIES ALAN SDirectorApr 24Option Exercise0.0010,638027,720Apr 27 04:48 PM
BARKER SAM LDirectorApr 24Option Exercise0.0010,638066,291Apr 27 04:46 PM
DEBBANE RAYMONDDirectorApr 24Option Exercise0.0010,6380327,521Apr 27 04:47 PM
Amouyal PhilippeDirectorApr 24Option Exercise0.0010,638027,006Apr 27 04:45 PM
Tessmer James FVP, Finance & AccountingMar 15Option Exercise3.3112,00039,72083,766Mar 16 07:45 PM
Tessmer James FVP, Finance & AccountingMar 15Sale6.9222,912158,44071,766Mar 16 07:45 PM
Artal International S.C.A.DirectorDec 16Buy3.2010,937,50035,000,00032,259,461Dec 17 02:43 PM
Invus Public Equities, L.P.DirectorDec 16Buy3.2010,937,50035,000,00032,259,461Dec 17 02:39 PM